Azacitidine plus luspatercept vs azacitidine alone for high-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two MDS treatments: a combination of two medicines (azacitidine plus luspatercept) versus azacitidine alone. It is for people with high-risk MDS who have not been treated yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of MDS that is considered high risk (doctors measure this with scores like IPSS).
- You must not have received any MDS treatment before.
- Your liver and kidney function tests must be within safe limits (less than 2 times the normal maximum).
- You should be generally well enough to care for yourself (ECOG score of 0, 1, or 2) and expected to live more than 6 months.
- You cannot have an active infection, other cancers, severe organ problems, or a history of bone marrow transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, lisaftoclax, combined with azacytidine for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if this combination can help control the disease better.
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
This Phase 3 trial tests whether doing an “allogeneic” stem cell transplant works best for people newly diagnosed with higher-risk MDS (a bone marrow disorder). It’s mainly for patients who are healthy enough to receive a transplant and haven’t started MDS treatment yet.
This Phase 2 study tests whether combining azacitidine and ruxolitinib can better control higher-risk bone marrow diseases (MDS/MPN, including CMML). It may help patients who are not good candidates for a stem cell transplant and who can safely take these medicines.
This trial tests whether adding high-dose vitamin C (ascorbate) to a standard chemotherapy drug (azacitidine) helps people with higher-risk myelodysplastic syndrome (MDS). It is for those who have had little or no prior treatment for MDS.
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Hear when a new Higher-risk Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.